Adenosquamous Carcinoma
8
2
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
12.5%
1 terminated out of 8 trials
80.0%
-6.5% vs benchmark
38%
3 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)
Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer